Cargando…

Probiotics at War Against Viruses: What Is Missing From the Picture?

Our world is now facing a multitude of novel infectious diseases. Bacterial infections are treated with antibiotics, albeit with increasing difficulty as many of the more common causes of infection have now developed broad spectrum antimicrobial resistance. However, there is now an even greater chal...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiwari, Santosh Kumar, Dicks, Leon M. T., Popov, Igor V., Karaseva, Alena, Ermakov, Alexey M., Suvorov, Alexander, Tagg, John R., Weeks, Richard, Chikindas, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468459/
https://www.ncbi.nlm.nih.gov/pubmed/32973697
http://dx.doi.org/10.3389/fmicb.2020.01877
_version_ 1783578222741422080
author Tiwari, Santosh Kumar
Dicks, Leon M. T.
Popov, Igor V.
Karaseva, Alena
Ermakov, Alexey M.
Suvorov, Alexander
Tagg, John R.
Weeks, Richard
Chikindas, Michael L.
author_facet Tiwari, Santosh Kumar
Dicks, Leon M. T.
Popov, Igor V.
Karaseva, Alena
Ermakov, Alexey M.
Suvorov, Alexander
Tagg, John R.
Weeks, Richard
Chikindas, Michael L.
author_sort Tiwari, Santosh Kumar
collection PubMed
description Our world is now facing a multitude of novel infectious diseases. Bacterial infections are treated with antibiotics, albeit with increasing difficulty as many of the more common causes of infection have now developed broad spectrum antimicrobial resistance. However, there is now an even greater challenge from both old and new viruses capable of causing respiratory, enteric, and urogenital infections. Reports of viruses resistant to frontline therapeutic drugs are steadily increasing and there is an urgent need to develop novel antiviral agents. Although this all makes sense, it seems rather strange that relatively little attention has been given to the antiviral capabilities of probiotics. Over the years, beneficial strains of lactic acid bacteria (LAB) have been successfully used to treat gastrointestinal, oral, and vaginal infections, and some can also effect a reduction in serum cholesterol levels. Some probiotics prevent gastrointestinal dysbiosis and, by doing so, reduce the risk of developing secondary infections. Other probiotics exhibit anti-tumor and immunomodulating properties, and in some studies, antiviral activities have been reported for probiotic bacteria and/or their metabolites. Unfortunately, the mechanistic basis of the observed beneficial effects of probiotics in countering viral infections is sometimes unclear. Interestingly, in COVID-19 patients, a clear decrease has been observed in cell numbers of Lactobacillus and Bifidobacterium spp., both of which are common sources of intestinal probiotics. The present review, specifically motivated by the need to implement effective new counters to SARS-CoV-2, focusses attention on viruses capable of co-infecting humans and other animals and specifically explores the potential of probiotic bacteria and their metabolites to intervene with the process of virus infection. The goal is to help to provide a more informed background for the planning of future probiotic-based antiviral research.
format Online
Article
Text
id pubmed-7468459
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74684592020-09-23 Probiotics at War Against Viruses: What Is Missing From the Picture? Tiwari, Santosh Kumar Dicks, Leon M. T. Popov, Igor V. Karaseva, Alena Ermakov, Alexey M. Suvorov, Alexander Tagg, John R. Weeks, Richard Chikindas, Michael L. Front Microbiol Microbiology Our world is now facing a multitude of novel infectious diseases. Bacterial infections are treated with antibiotics, albeit with increasing difficulty as many of the more common causes of infection have now developed broad spectrum antimicrobial resistance. However, there is now an even greater challenge from both old and new viruses capable of causing respiratory, enteric, and urogenital infections. Reports of viruses resistant to frontline therapeutic drugs are steadily increasing and there is an urgent need to develop novel antiviral agents. Although this all makes sense, it seems rather strange that relatively little attention has been given to the antiviral capabilities of probiotics. Over the years, beneficial strains of lactic acid bacteria (LAB) have been successfully used to treat gastrointestinal, oral, and vaginal infections, and some can also effect a reduction in serum cholesterol levels. Some probiotics prevent gastrointestinal dysbiosis and, by doing so, reduce the risk of developing secondary infections. Other probiotics exhibit anti-tumor and immunomodulating properties, and in some studies, antiviral activities have been reported for probiotic bacteria and/or their metabolites. Unfortunately, the mechanistic basis of the observed beneficial effects of probiotics in countering viral infections is sometimes unclear. Interestingly, in COVID-19 patients, a clear decrease has been observed in cell numbers of Lactobacillus and Bifidobacterium spp., both of which are common sources of intestinal probiotics. The present review, specifically motivated by the need to implement effective new counters to SARS-CoV-2, focusses attention on viruses capable of co-infecting humans and other animals and specifically explores the potential of probiotic bacteria and their metabolites to intervene with the process of virus infection. The goal is to help to provide a more informed background for the planning of future probiotic-based antiviral research. Frontiers Media S.A. 2020-08-20 /pmc/articles/PMC7468459/ /pubmed/32973697 http://dx.doi.org/10.3389/fmicb.2020.01877 Text en Copyright © 2020 Tiwari, Dicks, Popov, Karaseva, Ermakov, Suvorov, Tagg, Weeks and Chikindas. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Tiwari, Santosh Kumar
Dicks, Leon M. T.
Popov, Igor V.
Karaseva, Alena
Ermakov, Alexey M.
Suvorov, Alexander
Tagg, John R.
Weeks, Richard
Chikindas, Michael L.
Probiotics at War Against Viruses: What Is Missing From the Picture?
title Probiotics at War Against Viruses: What Is Missing From the Picture?
title_full Probiotics at War Against Viruses: What Is Missing From the Picture?
title_fullStr Probiotics at War Against Viruses: What Is Missing From the Picture?
title_full_unstemmed Probiotics at War Against Viruses: What Is Missing From the Picture?
title_short Probiotics at War Against Viruses: What Is Missing From the Picture?
title_sort probiotics at war against viruses: what is missing from the picture?
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468459/
https://www.ncbi.nlm.nih.gov/pubmed/32973697
http://dx.doi.org/10.3389/fmicb.2020.01877
work_keys_str_mv AT tiwarisantoshkumar probioticsatwaragainstviruseswhatismissingfromthepicture
AT dicksleonmt probioticsatwaragainstviruseswhatismissingfromthepicture
AT popovigorv probioticsatwaragainstviruseswhatismissingfromthepicture
AT karasevaalena probioticsatwaragainstviruseswhatismissingfromthepicture
AT ermakovalexeym probioticsatwaragainstviruseswhatismissingfromthepicture
AT suvorovalexander probioticsatwaragainstviruseswhatismissingfromthepicture
AT taggjohnr probioticsatwaragainstviruseswhatismissingfromthepicture
AT weeksrichard probioticsatwaragainstviruseswhatismissingfromthepicture
AT chikindasmichaell probioticsatwaragainstviruseswhatismissingfromthepicture